

## Chapter 40

# Hormone Myths Versus Medical Evidence

*Ron Rothenberg, M.D.*

*Clinical Professor, Family and Preventive Medicine,  
University of California San Diego School of Medicine, San Diego, California USA;  
Founder, California HealthSpan Institute*

### ABSTRACT

There are many myths surrounding hormone replacement therapies. The aim of this paper is to review the current medical literature surrounding these myths and to demonstrate the safety and efficacy of hormone replacement therapies.

### INTRODUCTION

There are many myths surrounding hormone replacement therapies, from the notion that thyroid hormone is dangerous for the heart, to the widespread belief that growth hormone replacement therapy (GHRT) increases the risk of cancer. The aim of this paper is to review the current medical literature surrounding these myths and to demonstrate the safety and efficacy of hormone replacement therapies.

### MYTH # 1: THYROID IS DANGEROUS FOR THE HEART

Our first patient is a 60-year-old physician with acute myocardial infarction (MI), congestive heart failure (CHF), and tachycardia. Laboratory results show that his TSH (thyroid stimulating hormone) is 3.5, free T4 is 1.3 (reference range 0.70-1.53 ng/dL), free T3 is 2.1 (reference range 2.3-4.2 pg/mL), and his reverse T3 is 380 (reference range 90-350 pg/mL). Would you treat this patient with thyroid? Would it be best to steer clear? Or, would optimizing his thyroid hormone improve the situation?

Is thyroid hormone bad for the heart? No. Yes, it is true that hyperthyroidism is associated with atrial fibrillation; however optimizing thyroid hormone is associated with numerous benefits<sup>1,2</sup>:

- Improves lipids
- Improves CHF
- Has a positive inotropic effect upon the heart
- Is vasodilatory
- Prevents maladaptive cardiac remodeling after acute MI
- Normalizes the QT interval, thus reducing the odds of lethal arrhythmias
- Improves C-reactive protein (CRP) and homocysteine levels
- Improves arterial stiffness and endothelial dysfunction.

What if a patient with cardiovascular disease has low T3? It is important to remember that T3 is the active hormone and T4 is the prohormone. The heart needs T3 as it is unable to convert T4 into T3. Signs of low T3 in cardiovascular disease include<sup>3</sup>:

- Bradycardia, narrowed pulse pressure, and diastolic hypertension
- Dyslipidemia
- Endothelial dysfunction
- Elevated CRP and homocysteine

Iervasi *et al* found that low T3 is a strong predictor of death in cardiovascular patients.<sup>4</sup> In this study, low T3 was defined as <3.1 pg/mL free T3, which is interesting because it is within the confines of the reference range (2.3 to 4.2 pg/mL), albeit in the bad half of the reference range – remember, as anti-aging physicians we want optimal levels, not reference range levels. Results showed that low T3 was the strongest independent predictor of death – more than dyslipidemia and more than a poor ejection fraction. Furthermore, the authors concluded that low T3 might be directly implicated in the poor prognosis of cardiac patients.

So, low T3 is associated with a poor prognosis, but what factors are associated with survival after an acute MI? A study of acute MI patients by Satar *et al* found that patients who survived had higher free T3 levels than those who died, and that non-survivors had higher TSH and reverse T3 than controls.<sup>5</sup> High reverse T3 levels are seen in a lot of critical clinical situations, such as MI and unstable angina,

because a survival mechanism is triggered by such circumstances. Unfortunately, it is a maladaptive survival mechanism, and it causes something called euthyroid sick syndrome (ESS). Patients with ESS have low T3 levels and increased reverse T3 levels (TSH and T4 may be in the reference range), so it is vital to order the right tests in order to detect ESS. Pavlou *et al* found that the degree of T3 decrease in patients with acute MI was proportional to the severity of cardiac damage sustained.<sup>6</sup>

New research suggests that we may soon be treating patients with patients with low T3 syndrome and ischemic or non-ischemic dilated cardiomyopathy with intravenous (IV) T3. At first thought, this sounds crazy. However, Pingitore *et al* showed that this treatment was both safe and effective.<sup>7</sup> Patients were given an infusion of T3 in order to restore circulating T3 levels to within the normal range. No adverse side effects were observed. Heart rate and B-type natriuretic peptide levels decreased significantly after infusion and ventricular performance improved. Perhaps the notion of IV T3 is not so crazy after all. If further studies are successful, we may well be giving patients IV T3 to treat CHF and acute MI.

After MI, the body attempts to remodel the ischemic area. However, once again, a maladaptive mechanism comes into play and the body employs fetal-type myosin to remodel the damaged tissue. Thus, the body thinks a new heart being born, and the upshot of this is that you do not get appropriate remodeling of the heart. Research suggests that thyroid hormone prevents this maladaptive remodeling.<sup>8-10</sup>

So, we can see that thyroid hormone is clearly not dangerous for the heart. It is very important to measure free T3 and reverse T3 in cardiac patients, and it is equally important not to be afraid of optimizing T3 – it should be in the upper third of the reference range (3.5-4.2 pg/mL). A patient's life may well depend on it. Treat mild hypothyroidism by optimizing free T3 to reduce all components of metabolic syndrome. Do not rely on the TSH. Look at the patient's clinical picture and look at free T3, and remember that it is important to consider symptoms, not just numbers.

## **MYTH # 2: TESTOSTERONE CAUSES PROSTATE CANCER TO GROW**

Our second patient is a 60-year-old physician with a history of prostate cancer. He was treated with a radical prostatectomy 2 years ago. The clinical picture (irritable, low libido, erectile dysfunction) and laboratory results – testosterone 350 ng/dL (reference range 300-1000 ng/dL), free testosterone 6 pg/mL (reference range 8-24 pg/mL), sex hormone binding globulin (SHBG) 40 nmol/L (reference range 30-65 nmol/L), estradiol (E2) 25 ng/dL (reference range 15-50 ng/dL) – both suggest hypogonadism. He is interested in testosterone replacement therapy (TRT); however his wife is worried that TRT will increase his risk of cancer recurrence. Would you treat the patient with testosterone?

The bottom line is that testosterone does not cause prostate cancer to grow. The notion that testosterone causes prostate cancer to grow was based on one case report from 1941 – one patient!<sup>11</sup> There is no relationship between testosterone, dihydrotestosterone, estradiol, and prostate cancer, and there are no reports of prostate cancer in men treated with testosterone after radical prostatectomy.

Results of a perspective study of 11,606 men by Khaw *et al* led the authors to conclude: “In men, endogenous testosterone concentrations are inversely related to mortality due to cardiovascular disease and all causes.”<sup>12</sup> The authors also write: “Prospective studies or supplementation studies, reviewed elsewhere, have not reported significant relationships of endogenous testosterone concentrations or of testosterone supplementation with prostate cancer. Although in the present analysis, there was insufficient power to examine the relationships with prostate or other specific cancers, we observed an inverse relationship of endogenous testosterone concentrations with cancer mortality.”

Another study, this time a review of 18 prospective studies that included 3886 men with incident prostate cancer and 6438 control subjects, examined the association between endogenous sex hormones and prostate cancer risk.<sup>13</sup> No associations were found between the risk of prostate cancer and serum concentrations of testosterone, calculated free testosterone, dihydrotestosterone, dehydroepiandrosterone sulfate, androstenedione, androstanediol glucuronide, estradiol, or calculated free estradiol.

So, there is plenty of evidence to show that testosterone does not increase the risk of prostate cancer. There is also evidence showing that endogenous testosterone concentrations are inversely related to mortality due to cardiovascular disease and all causes, but is there any evidence to show that treating men with testosterone after radical prostatectomy is safe? Yes, there is. Agarwal and Oefelein studied 10 hypogonadal patients treated with radical prostatectomy for organ-confined prostate cancer to determine if TRT could be administered safely without causing recurrent prostate tumor.<sup>14</sup> Results

showed that after receiving TRT for approximately 19 months total testosterone levels and hypogonadal symptoms had improved significantly, and there were no prostate cancer recurrences or increases in PSA. These results led the authors to conclude: “In highly select patients after radical prostatectomy TRT can be administered carefully and with benefit to hypogonadal patients with prostate cancer.”

Not everyone will be comfortable with prescribing TRT to men who have undergone radical prostatectomy; however it is clear that the medical literature does support the carefully monitored use of TRT in men with a history of prostate cancer.<sup>15-18</sup>

### **MYTH #3: TESTOSTERONE CAUSES ANGRY AND AGGRESSIVE BEHAVIOR**

So, after careful consideration, we have decided to put patient #2 on TRT. However, Patient #2 is known to have a short temper, and now that his wife’s fears concerning prostate cancer recurrence have been put to rest, she is concerned about so-called “roid rage”. In short, she is worried that TRT will make him angry and aggressive. Is this true?

No, it is not. This is just another hormone replacement myth. In fact, TRT has quite the opposite effect on behavior. Much of the bad press about TRT stems from media stories about anabolic steroid abuse – we are not concerned with abusing anabolic steroids, we are concerned with restoring testosterone to physiologic levels. Studies have shown that men who have their testosterone levels restored with TRT are less likely to suffer from depression, are less moody, more sociable and gregarious, and have more energy.<sup>19</sup> O’Connor *et al* investigated the effects of TRT on self- and partner-reported aggression and mood.<sup>20</sup> Eight hypogonadal men received 200 mg intramuscular testosterone biweekly for 8 weeks. Results showed that TRT led to significant reductions in negative mood (tension, anger, and fatigue). Furthermore, there was no increase in self- and partner-reported aggression or mood disturbances. Thus, we can conclude that TRT does not cause or worsen angry or aggressive behavior.

### **MYTH #4: GROWTH HORMONE CAUSES CANCER**

Patient #3 is a 60-year-old woman with a clinical and laboratory picture of adult growth hormone (GH) deficiency (AGHD). However, she also has a strong family history of breast cancer. Is it safe to treat her for AGHD? Does GH cause cancer?

A paper by Jenkins *et al* entitled “Does growth hormone cause cancer?” concluded: “Extensive studies of the outcome of GH replacement in childhood cancer survivors show no evidence of an excess of *de novo* cancers, and more recent surveillance of children and adults treated with GH has revealed no increase in observed cancer risk.”<sup>21</sup>

As GH increases levels of insulin-like growth factor-1 (IGF-1), could it be possible that the increase in IGF-1 levels associated with GH replacement therapy (GHRT) increases the risk of cancer? Results of a case-control study by Schernhammer *et al* led the authors to conclude: “Circulating IGF-I, IGFBP-1, IGFBP-3, and GH levels appear to have no important association with breast cancer risk in a large cohort of premenopausal women.”<sup>22</sup>

If you look at the package insert for GH it says that it should not be used in patients with an active malignancy. However, the Growth Hormone Research Society published a paper in the *Journal of Clinical Endocrinology and Metabolism*, saying that there is no data to support this labeling, and that current knowledge does not warrant additional warning about cancer risk.<sup>23</sup> The authors of this paper say that this line should be removed from the package insert because there is no evidence to show that GH increases cancer recurrence or *de novo* cancer or leukemia. In conclusion, the notion that GH causes cancer is another myth.<sup>24</sup>

### **MYTH #5: ADULT GROWTH HORMONE DEFICIENCY IS ONLY SEEN IN PATIENTS WITH SEVERE MULTIPLE PITUITARY DEFICIENCIES SINCE CHILDHOOD**

After taking a detailed medical history of Patient #3, we learn that she was thrown from her horse a year ago. In fact, she had a head injury and was comatose for four hours. Results of a CT scan taken at that time showed cerebral contusion. Does AGHD only occur in patients who have had severe multiple pituitary deficiencies since childhood? Or, is that simply a myth? Is there a relationship between traumatic brain injury (TBI) and AGHD?

Yes, it is a myth, and yes there is a relationship between TBI and AGHD. GH deficiency is common in survivors of moderate-to-severe, and even mild, TBI. The onset of TBI-induced GH deficiency

can present up to a year after the injury, and therefore assessment of the GH/IGF-1 axis is important in anyone with a history of TBI.

A review by Popovic *et al* showed that some degree of hypopituitarism is found in 35-40% of TBI patients, and suggested that untreated TBI-induced hypopituitarism contributes to the chronic neurobehavioral problems seen in many head-injured patients.<sup>25</sup> Preliminary data suggests that people suffering from TBI-induced hypopituitarism experience significant improvements in concentration, memory, depression, anxiety, and fatigue when treated with GH. The authors of this review concluded that pituitary failure is poorly recognized and can occur even with minor head injuries.<sup>26,27</sup>

Thus, all TBI, cerebrovascular accident, and subarachnoid hemorrhage patients should be evaluated for AGHD within a year of the event, and they should be treated if a deficiency exists. In the future, it may be possible to treat all TBI patients with GH if they have symptoms of GH deficiency, however at present patients need to have been given a diagnosis of AGHD before they can be treated.

## **MYTH #6: PROGESTERONE TREATMENT IS ONLY FOR MENOPAUSAL WOMEN WHO HAVE A UTERUS**

Is there another hormone therapy that could have helped Patient #3 when she fell off her horse? Could progesterone have helped her, or is progesterone treatment only for menopausal women who have a uterus?

Progesterone is neuroprotective. There is basic science to support this and now there are human trials. Pettus *et al* found that when progesterone is given after TBI it reduces the initial cytotoxic surge of inflammatory factors, decreases levels of nuclear factor kappa beta (NF $\kappa$ B), and decreases levels of inflammatory eicosanoids.<sup>28</sup> So, how does progesterone exert this neuroprotective effect? The neuroprotective properties of progesterone are probably derived from the action of allopregnanolone (AP $\alpha$ ), a neuroactive metabolite of progesterone, which turns on neuronal stem cells. Wang *et al* found that AP $\alpha$  promotes the proliferation of rodent neuroprogenitor cells (NPCs) derived from the hippocampus, and increases human neural stem cells (hNSCs) derived from the cerebral cortex. Results also showed that AP $\alpha$  regulates cell-cycle gene and protein expression.<sup>29</sup>

Could we have treated Patient #3 with progesterone? Research published in the last few years suggests that progesterone may well play an important role in the treatment of TBI. First there was the ProTECT study, a randomized, placebo-controlled, clinical trial of 100 patients evaluating the safety and potential efficacy of progesterone in patients with TBI, which was the first human study to prove the benefits of progesterone as a neuroprotective agent.<sup>30</sup> The study used the both the Glasgow Coma Scale (GCS) and the Glasgow Outcome Scale (GOS) score. The GCS was used to record the condition of the patient upon admission to hospital and the GOS was used to record their condition after treatment. The GOS ranges from 1 to 5: 1 – dead, 2 – permanent vegetative state, 3 – severe disability, 4 – moderate disability, 5 – good recovery. The patients in the study had a GCS of between 4 (signifying a severe TBI) and 12 (signifying a moderate TBI) when they were admitted to hospital. Patients were randomized on a 4:1 basis to receive either intravenous progesterone or placebo. Those selected for progesterone treatment were given progesterone via intravenous drip for three days. Each patient received 37 mg progesterone per kilogram of body weight, which. Results showed that the 30-day mortality rate was cut in half in those treated with progesterone. Severe brain injury (GCS 4-8) survivors in both progesterone and control groups scored poorly on the GOS. However, moderate brain injury (GCS 9-12) survivors in the progesterone group were significantly more likely to receive a moderate or good GOS – that is a GOS of 4 or 5. In the placebo group none of the seven patients with a moderate brain injury were given a moderate or good GOS; however in the progesterone group ten out of eighteen patients were given a moderate or good GOS.

Another study of great interest is a prospective, randomized, placebo-controlled trial by Xiao *et al*.<sup>31</sup> This study involved 230 TBI patients who had a GCS score of 8 or less on admission. Therefore all the patients in this study had a severe TBI. Patients were randomly assigned to receive either progesterone or placebo. The primary endpoint was the GOS score 3-months and 6-months after injury. Results showed that GOS scores were more favorable and modified Functional Independence Measure scores were higher in patients treated with progesterone than in those given placebo. Furthermore, at 6-month follow-up the mortality rate of the progesterone group was significantly lower than that of the placebo group.

The results of these studies are extremely promising. However, using progesterone to treat TBI is still classed as an experimental treatment. Despite this, I know that if I sustained a brain injury I would certainly want to be treated with it.

### **MYTH #7: PROGESTERONE EQUALS PROGESTIN**

Patient #3 is pleased that treating her with progesterone when she fell off her horse would, most likely, improve her chances of making a full recovery; however having read reports about the Women's Health Initiative Study, she is concerned that being treated with progesterone will increase her risk of cancer and ischemic heart disease. Is that the case? Is progesterone the same as progestin?

Fournier *et al* compared the association between different forms of hormone replacement therapy (HRT) and breast cancer risk, using data from the French E3N cohort study – a large, ongoing study of more than 80,000 women.<sup>32</sup> Results showed that women treated with bioidentical estradiol and progesterone were no more likely to develop breast cancer rates than women who had never used any form of HRT. However, women treated with estradiol and progestin (Provera) had a 69% increased risk of developing breast cancer.

Other research has shown that more progesterone a woman is exposed to over the course of her life, the lower her risk of breast cancer.<sup>33</sup> So, let's make it clear once and for all – progesterone and progestin are not the same.

### **MYTH #8-18: THE MANY VITAMIN D MYTHS**

Patient #4 is a 60-year-old physician with a family history of colon cancer and autoimmune disease. She takes a daily multivitamin that contains 1000 IU of vitamin D3 and her 25-(OH) vitamin D3 level is 33 ng/mL (reference range 33-105 ng/mL). Should Patient #4 increase her dose of vitamin D3?

There are so many myths surrounding vitamin D. First and foremost, is the myth that vitamin D is a vitamin. Vitamin D is not a vitamin, it is actually a steroid hormone. Vitamin D is produced in one part of the body (the skin), and then travels to a remote site, where it exerts an endocrine effect. Thus, it fulfills the definition of a hormone. Another vitamin D myth is that its only function is calcium regulation. That idea has been well and truly debunked in recent years. Then there is the idea that 1000 IUs a day is more than enough, which is simply not true. Other myths of interest include:

- Most people living in the US get adequate amounts of vitamin D – not true (see below).
- Extreme care must be taken to avoid toxicity – not true! There have been numerous studies on vitamin D toxicity and no toxicity has been seen in doses lower than 30,000 IU/day (200 ng/mL). An excess of vitamin D causes hypercalcemia, however all known cases of vitamin D toxicity with hypercalcemia have involved intakes of 40,000 IU or more per day.
- Spending 15 minutes in the sun each day enables the body to produce ample amounts of vitamin D – that may be true if you are sitting on a beach in Hawaii at noon wearing nothing but a bikini, but for the vast majority of us that is a myth. If you live above 35 degrees latitude, the body is unable to produce adequate amounts of vitamin D from the winter sun.
- Eating a balanced diet will provide adequate amounts of vitamin D – not true! Vitamin D is present, in small amounts, in only a handful of foods – oily fish, eggs, and fortified foods. Thus it is very unlikely that adequate amounts could be obtained from the diet.
- Vitamin D does not prevent cancer – it does (see below).
- Vitamin D does not prevent autoimmune disease – it does (see below).
- Vitamin D does not prevent acute MI and heart disease – it does (see below).

As mentioned above, the notion that most people living in the US get adequate amounts of vitamin D is far from true. Research has shown that Vitamin D deficiency is present among all age groups of US citizens from children to the elderly, and especially in African-Americans.<sup>34</sup> Studies have shown that the prevalence of low 25-(OH) D levels (<20 ng/mL) is approximately 36% in young adults aged 18-29,<sup>35</sup> 42% of African-American women aged 15-49,<sup>36</sup> 41% of outpatients aged 49-83,<sup>37</sup> and 57% of inpatients.<sup>38</sup> In Europe, it is believed that between 28 and 100% of healthy adults and 70-100% of hospitalized adults have low 25-(OH) D levels (<20 ng/mL).<sup>37,39,40</sup>

Research has shown that the incidence of many diseases could be dramatically reduced by increasing serum 25-(OH) D levels, and by looking at the list below, it is easy to see why vitamin D has become a very hot topic in recent years:

- Increasing serum 25-(OH) D levels to 35 ng/mL could prevent 30% of MI in men<sup>42</sup> and reduce the risk of fracture in elderly people by 50%.<sup>43</sup>
- Increasing serum 25-(OH) D levels to approximately 40 ng/mL could reduce the risk of cancer in postmenopausal women by 35%<sup>44</sup> and reduce the risk of falls in elderly people by 50%.<sup>45</sup>
- Increasing serum 25-(OH) D levels to 50 ng/mL could reduce the incidence of breast cancer by as much as 80%,<sup>46</sup> multiple sclerosis by as much as 60%,<sup>47</sup> and type I diabetes by up to 50%.<sup>48</sup>

Why is vitamin D so beneficial? There is no clear answer at present. However, anything that has such wide-ranging benefits has to possess the ability to modulate inflammation. Indeed, studies have shown that vitamin D inhibits nuclear factor- $\kappa$ B (NF- $\kappa$ B)<sup>49</sup> – a protein that plays a key role in the inflammatory response and in the proliferation of cancer cells. It has also been shown to lower levels of the inflammatory marker CRP.<sup>50</sup> Thus, it is vital that we ensure our patients are getting plenty of vitamin D.

What about Patient #4, does she need to increase her daily dose of vitamin D3? Yes. The reference range for 25-(OH) D is 33-105 ng/mL. Given the evidence published in the medical literature over the last few years, it is advisable to try and keep patients at the top end of the reference range – so, we should be aiming for 75-100 ng/mL. The optimal dose is 5000-15,000 IU/day, however this should be lowered for people who get a lot of sun exposure. It is also advisable to regularly check serum calcium in patients who take supplementary vitamin D, just to ensure there is no risk of hypercalcemia.

## CONCLUDING REMARKS

There are many myths surrounding hormone replacement therapies, however from the evidence presented above, we can see that not one of them is true. Hormone optimization provides us with an extremely powerful anti-aging tool to maximize quality of life. It is important to note that there is increasing evidence to suggest that hormones may also play an important role in the treatment of cardiovascular trauma and TBI.

## REFERENCES

1. Asvold BO, Vatten LJ, Nilsne TI, Bjørø T. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. *Eur J Endocrinol*. 2007;156:181-186.
2. Razvi S, Shakoor A, Vanderpump M, Weaver JU, Pearce SH. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a metaanalysis. *J Clin Endocrinol Metab*. 2008;93:2998-3007.
3. Fernández-Real JM, López-Bermejo A, Castro A, Casamitjana R, Ricart W. Thyroid function is intrinsically linked to insulin sensitivity and endothelium-dependent vasodilation in healthy euthyroid subjects. *J Clin Endocrinol Metab*. 2006;91:3337-3343.
4. Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scarlattini M, L'Abbate A, Donato L. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. *Circulation*. 2003;107:708-713.
5. Satar S, Seydaoglu G, Avci A, Sebe A, Karcioğlu O, Topal M. Prognostic value of thyroid hormone levels in acute myocardial infarction: just an epiphenomenon? *Am Heart Hosp J*. 2005;3:227-233.
6. Pavlou HN, Kliridis PA, Panagiotopoulos AA, Goritsas CP, Vassilakos PJ. Euthyroid sick syndrome in acute ischemic syndromes. *Angiology*. 2002;53:699-707.
7. Pingitore A, Galli E, Barison A, Iervasi A, Scarlattini M, Nucci D, L'abbate A, Mariotti R, Iervasi G. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. *J Clin Endocrinol Metab*. 2008;93:1351-1358.
8. Pantos C, Mourouzis I, Cokkinos DV. Rebuilding the post-infarcted myocardium by activating 'physiologic' hypertrophic signaling pathways: the thyroid hormone paradigm. *Heart Fail Rev*. 2008 Sep 5. [Epub ahead of print].
9. Pantos C, Mourouzis I, Xinaris C, Papadopoulou-Daifoti Z, Cokkinos D. Thyroid hormone and "cardiac metamorphosis": potential therapeutic implications. *Pharmacol Ther*. 2008;118:277-294.

10. Klein I, Danzi S. Thyroid hormone treatment to mend a broken heart. *J Clin Endocrinol Metab.* 2008;93:1172-1174
11. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. *Eur Urol.* 2006;50:935-939.
12. Khaw KT, Dowsett M, Folkard E, Bingham S, Wareham N, Luben R, Welch A, Day N. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. *Circulation.* 2007;116:2694-2701.
13. Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. *J Natl Cancer Inst.* 2008;100:170-183.
14. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. *J Urol.* 2005;173:533-536.
15. Raynaud JP. Prostate cancer risk in testosterone-treated men. *J Steroid Biochem Mol Biol.* 2006;102:261-266.
16. Khera M, Lipshultz LI. The role of testosterone replacement therapy following radical prostatectomy. *Urol Clin North Am.* 2007;34:549-553.
17. Morgentaler A, Schulman C. Testosterone and prostate safety. *Front Horm Res.* 2009;37:197-203.
18. Dobs AS, Morgentaler A. Does testosterone therapy increase the risk of prostate cancer? *Endocr Pract.* 2008;14:904-911.
19. Zitzmann M. Testosterone and the brain. *Aging Male.* 2006;9:195-199.
20. O'Connor DB, Archer J, Hair WM, Wu FC. Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men. *Physiol Behav.* 2002;75:557-566.
21. Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Jenkins PJ, Mukherjee A, Shalet SM. *Clin Endocrinol (Oxf).* 2006;64:115-121.
22. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. *Endocr Relat Cancer.* 2006;13:583-592.
23. [No authors listed] Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. *J Clin Endocrinol Metab.* 2001;86:1868-1870.
24. Molitch ME. Diagnosis of GH deficiency in adults--how good do the criteria need to be? *J Clin Endocrinol Metab* 2002 Feb;87(2):473-6
25. Popovic V, Aimaretti G, Casanueva FF, Ghigo E. Hypopituitarism following traumatic brain injury. *Growth Horm IGF Res.* 2005;15:177-184.
26. Rothman MS, Arciniegas DB, Filley CM, Wierman ME. The neuroendocrine effects of traumatic brain injury. *J Neuropsychiatry Clin Neurosci.* 2007;19:363-372.
27. Behan LA, Phillips J, Thompson CJ, Agha A. Neuroendocrine disorders after traumatic brain injury. *J Neurol Neurosurg Psychiatry.* 2008;79:753-759.
28. Pettus EH, Wright DW, Stein DG, Hoffman SW. Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. *Brain Res.* 2005;1049:112-119.
29. Djebaili M, Guo Q, Pettus EH, Hoffman SW, Stein DG. The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. *J Neurotrauma.* 2005;22:106-118.
30. Wang JM, Johnston PB, Ball BG, Brinton RD. The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. *J Neurosci.* 2005;25:4706-4718.
31. Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. *Crit Care.* 2008;12:R61.
32. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. *Breast Cancer Res Treat.* 2008;107:103-111.
33. Campagnoli C, Abbà C, Ambroggio S, Peris C. Pregnancy progesterone and progestins in relation to breast cancer risk. *J Steroid Biochem Mol Biol.* 2005;97:441-450.
34. Holick MF. High prevalence of vitamin D inadequacy and implications for health. *Mayo Clin Proc.* 2006;81:353-373.
35. Tangpricha V, Pearce EN, Chen TC, Holick MF. Vitamin D insufficiency among free-living healthy young adults. *Am J Med.* 2002;112:659-662.
36. Nesby-O'Dell S, Scanlon KS, Cogswell ME, Gillespie C, Hollis BW, Looker AC, Allen C, Dougherty C, Gunter EW, Bowman BA. Hypovitaminosis D prevalence and determinants among African American and

- white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. *Am J Clin Nutr*. 2002;76:187-192.
37. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency [letter]. *Lancet*. 1998;351:805-806.
  38. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS. Hypovitaminosis D in medical inpatients. *N Engl J Med*. 1998;338:777-783.
  39. McKenna MJ. Differences in vitamin D status between countries in young adults and the elderly. *Am J Med*. 1992;93:69-77.
  40. Isaia G, Giorgino R, Rini GB, Bevilacqua M, Maugeri D, Adami S. Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. *Osteoporos Int*. 2003;14:577-582.
  41. Passeri G, Pini G, Troiano L, Vescovini R, Sansoni P, Passeri M, Guerresi P, Delsignore R, Pedrazzoni M, Franceschi C. Low vitamin D status, high bone turnover, and bone fractures in centenarians. *J Clin Endocrinol Metab*. 2003;88:5109-5115.
  42. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. *Arch Intern Med*. 2008;168:1174-80.
  43. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. *JAMA*. 2005;293:2257-2264.
  44. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. *Am J Clin Nutr*. 2007;85:1586-1591.
  45. Broe KE, Chen TC, Weinberg J, Bischoff-Ferrari HA, Holick MF, Kiel DP. A higher dose of vitamin d reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. *J Am Geriatr Soc*. 2007;55:234-239.
  46. Garland CF, Gorham ED, Mohr SB, Grant WB, Garland FC. Breast cancer risk according to serum 25-hydroxyvitamin D: Meta-analysis of dose-response. Presented at: American Association for Cancer Research Annual Meeting; April 12-16, 2008; San Diego, California.
  47. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. *JAMA*. 2006;296:2832-2838.
  48. Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. *Lancet*. 2001;358:1500-1503.
  49. Szeto FL, Sun J, Kong J, Duan Y, Liao A, Madara JL, Li YC. Involvement of the vitamin D receptor in the regulation of NF-kappaB activity in fibroblasts. *J Steroid Biochem Mol Biol*. 2007;103:563-566.
  50. Boxer RS, Dauser DA, Walsh SJ, Hager WD, Kenny AM. The association between vitamin D and inflammation with the 6-minute walk and frailty in patients with heart failure. *J Am Geriatr Soc*. 2008;56:454-461.

## ABOUT THE AUTHOR

As a pioneer in the field of Anti-Aging Medicine, Dr. Ron Rothenberg was one of the first physicians to be recognized for his expertise to become fully board certified in the specialty. Dr. Rothenberg founded the California HealthSpan Institute in Encinitas, California in 1997 with a commitment to transforming our understanding of and finding treatment for aging as a disease. He received his MD from Columbia University, College of Physicians and Surgeons in 1970. Dr. Rothenberg performed his residency at Los Angeles County- University of Southern California (USC) Medical Center and is also board certified in Emergency Medicine. He received academic appointment to the University of California-San Diego (UCSD) School of Medicine Clinical Faculty in 1997 and was promoted to full Clinical Professor of Preventive and Family Medicine in 1989. Dr. Rothenberg is an Attending Physician and Director of Medical Education at Scrips Memorial Hospital in Encinitas, California.